What it is
5-Amino-1MQ (5A-1MQ) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), not a peptide.
NNMT shows up in metabolic and adipose-tissue literature, but that does not establish a validated human SQ protocol.
Evidence boundary
Research reference only.
Preparation and measurement
The listed 50 mg vial has a 3 mL capacity, so 50 mg + 3 mL bacteriostatic water = 16.67 mg/mL. On a U-100 syringe, 1 unit (0.01 mL) corresponds to approximately 167 mcg at this concentration.
The shared calculator uses the same 50 mg / 3 mL baseline. A different vial amount or diluent volume changes every unit conversion.
Reference schedule
| Phase | Dose | Draw / measure | Frequency | Weekly total |
|---|---|---|---|---|
| Days 1–2 | 2.5 mg | 15 U (0.15 mL) | Once daily, SQ | Short introductory phase; not a full-week total |
| Days 3+ | 5 mg | 30 U (0.30 mL) | Once daily, SQ | 35 mg/week while active |
| Split-dose source variant | 2.5 mg per administration | 15 U (0.15 mL) per administration | Twice daily, SQ | 35 mg/week while active |
Days 1–2
- Dose
- 2.5 mg
- Draw / measure
- 15 U (0.15 mL)
- Frequency
- Once daily, SQ
- Weekly total
- Short introductory phase; not a full-week total
Days 3+
- Dose
- 5 mg
- Draw / measure
- 30 U (0.30 mL)
- Frequency
- Once daily, SQ
- Weekly total
- 35 mg/week while active
Split-dose source variant
- Dose
- 2.5 mg per administration
- Draw / measure
- 15 U (0.15 mL) per administration
- Frequency
- Twice daily, SQ
- Weekly total
- 35 mg/week while active
Weekly totals apply only during the active phase shown. The alternatives are separate reported schedules, not instructions to combine or escalate automatically.
Titration rules
-
The source separates a short 2.5 mg tolerance phase from the 5 mg once-daily reference row.
-
The twice-daily row is a separate split-dose convention with the same 5 mg total daily exposure; it is not an add-on to the once-daily row.
-
No human trial establishes an optimal escalation sequence, so these rows should not be presented as a validated treatment plan.
-
Source-specific study endpoints
-
Changes in formulation, vial amount, or diluent volume, because those invalidate the listed U-100 conversions
-
The absence of robust human long-term safety and SQ pharmacokinetic data
Practical rules
- Keep the route explicitly SQ throughout this reference.
- Do not use the calculator output for a vial or dilution that differs from the stated 50 mg / 3 mL convention.
- Sources: PeptideDosing protocol for the reported schedule; Dimet-Wiley et al., Scientific Reports (2022) for preclinical NNMT-inhibitor context.